TheEdgeResearch
Home / Stocks / FUSN

Fusion Pharmaceuticals Inc. (FUSN)

NASDAQ Healthcare Biotechnology
$21.55 ▲ +0.14%
Market Cap
$1.83B
Sector
Healthcare
Industry
Biotechnology
Beta
-0.69
52-Wk Range
2.31-21.6
CEO
John F. Valliant
Country
CA
Currency
USD

Fusion Pharmaceuticals Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Hamilton, ON, CA. The stock last traded at $21.55, up 0.14% on the session, giving a market capitalisation of $1.83B. On trailing twelve-month figures it carries a trailing P/E of -14.86, a net margin of -4588.8%. Its beta of -0.69 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-14.86
Price / Sales
886.38
Price / Book
6.36
EV / EBITDA
-20.79
Gross margin
35.0%
Operating margin
-4798.5%
Net margin
-4588.8%
Return on equity
—
Debt / equity
0.23
Current ratio
15.01
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Global Select
Employees
101
IPO date
2020-06-26
Headquarters
Hamilton, ON, CA
About Fusion Pharmaceuticals Inc.

Fusion Pharmaceuticals Inc. is a clinical-stage oncology enterprise focused on creating precise radiopharmaceutical therapies. The company utilizes its groundbreaking Targeted Alpha Therapies platform, which incorporates its exclusive Fast-Clear linker technology. This innovative system enables the attachment of alpha particle-emitting isotopes to diverse targeting molecules, facilitating the targeted delivery of these potent payloads directly to cancerous growths. Its leading investigational compound, FPI-1434, is currently progressing through Phase 1 clinical trials as a singular treatment for individuals suffering from solid tumors that express the insulin-like growth factor 1 receptor. Beyond this, Fusion is conducting preclinical research into FPI-1434's effectiveness in conjunction with existing checkpoint inhibitors and DNA damage response inhibitors. These studies aim to thoroughly evaluate its anti-tumor effects, ideal dosage regimens, and pharmacological interactions within combination therapies. Furthermore, the firm is moving its earlier-stage candidate, FPI-1966, into clinical evaluation for the management of head and neck, and bladder cancers exhibiting fibroblast growth factor receptor. Fusion Pharmaceuticals also maintains a strategic partnership with AstraZeneca UK Limited, collaborating on the identification, advancement, and market introduction of alpha-emitting radiopharmaceuticals and combined cancer treatments. The company, established in 2014, is headquartered in Hamilton, Canada.

Comparable companies

Fusion Pharmaceuticals Inc. is most often compared with the following Healthcare names:

AMAMASTHBLUCALTCINCCTICDICELBPHPNTPRVB
More research on FUSN
FUSN technical analysis FUSN TheEdge Score Compare against peers
Open full interactive analysis & DCF →